CRISPR Therapeutics' Q3 saw reduced expenses and slow Casgevy launch, resulting in a revenue miss. Read why I am neutral on ...

Could advances in CRISPR technology be the solution? In the last decade, a new immunotherapy tool has entered the clinic. T cells engineered to express chimeric antigen receptors, known as CAR T ...